Form 4: Nuvation Bio Inc. CFO Acquires 500,000 Stock Options

Philippe Sauvage, CFO of Nuvation Bio Inc., was granted 500,000 stock options on February 28, 2025.

Summary

• On February 28, 2025, Philippe Sauvage, the Chief Financial Officer of Nuvation Bio Inc. [NUVB], acquired 500,000 stock options.
• The options have an exercise price of $1.97.
• The options vest as to 25% on the one-year anniversary of February 28, 2025, and then monthly over the following 36 months, contingent upon continuous service.
• The expiration date for these options is February 27, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely grant stock options to their executives.
• The vesting schedule of 25% after one year followed by monthly vesting over three years is a typical arrangement.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the CFO.
• Employees may see this as a sign of confidence in the company's future.

Key Dates